KLRA

Kailera Therapeutics Inc

May 15 • 04:00PM ET

21.04

-0.46 -2.14 %

Healthcare • Biotechnology • USA • Mid • NASD

Index	-	P/E	-	EPS (ttm)	-	Insider Own	32.50%	Shs Outstand	129.54M	Perf Week	-2.00%
Market Cap	2.73B	Forward P/E	-	EPS next Y	-3.55	Insider Trans	94.20%	Shs Float	89.34M	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	12.18%	Short Float	2.19%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-153.84%	Inst Trans	24.69%	Short Ratio	1.66	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-0.61%	ROA	-	Short Interest	1.95M	Perf YTD	-19.08%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	28.23 -25.46%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	20.86 0.84%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.13% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.01	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.64	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-10.62%	Beta	-	Target Price	42.75
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-11.06%	Rel Volume	0.41	Prev Close	21.50
Employees	145	LT Debt/Eq	-	Earnings	-	SMA200	-11.06%	Avg Volume	1.18M	Price	21.04
IPO	Apr 17, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	482,218	Change	-2.14%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-26	Initiated	William Blair	Outperform
May-12-26	Initiated	TD Cowen	Buy	$57
May-12-26	Initiated	Leerink Partners	Outperform	$36
May-12-26	Initiated	JP Morgan	Overweight	$30
May-12-26	Initiated	Jefferies	Buy	$48
May-12-26	Initiated	Evercore ISI	Outperform

May-13-26 07:30AM	Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire) -5.34%
May-12-26 12:50PM	Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity (Investor's Business Daily)
Apr-20-26 04:05PM	Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.35%

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.

M.B.A.Mr. Ronald C. Renaud Jr.

M.S.Mr. Paul Douglas Burgess J.D.

Chief Commercial OfficerMs. Jamie Beth Coleman

Chief Financial OfficerMr. Douglas W. Pagan M.B.A.

Vice President of Corporate Communications & Investor RelationsMaura Gavaghan

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RTW INVESTMENTS, LP	10% Owner	Apr 20 '26	Buy	16.00	500,000	8,000,000	10,776,820	Apr 22 04:15 PM
BAIN CAPITAL INVESTORS LLC	10% Owner	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:10 PM
Koppel Adam	Director	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:08 PM
Bain Capital Life Sciences Inv	10% Owner	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:01 PM
Kaplan Andrew T.	Director	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLRA

Kailera Therapeutics Inc

Upgrade your Finviz experience